Roswell Park Research Identifies Cells That May Be Responsible for Prostate Cancer Recurrence
Team discovers a dormant, treatment-resistant population of normal stem cells in the prostate
- Research team found small number of unique, dormant stem cells in the prostate
- These stem cells are molecularly similar to aggressive prostate cancer cells
- Findings could lead to development of targeted prostate cancer therapy
Newswise — BUFFALO, N.Y. — Although men with prostate cancer usually respond to standard treatment with hormone therapy or chemotherapy, many will eventually experience progression or recurrence despite treatment — particularly those with high-risk or aggressive forms of the disease. In preclinical laboratory research, a team led by Dean Tang, PhD, Chair of Pharmacology and Therapeutics at Roswell Park Cancer Institute has discovered a unique population of normal stem cells that are intrinsically resistant to conventional treatments and may enable prostate cancer relapse. In a new publication in the journal Stem Cell Reports, the team reports its development of a novel preclinical model that allows not only the labeling but also the purification of this rare but persistent population of prostate stem cells, which are dormant and, strikingly, resemble high-risk prostate cancer at the molecular level.
The normal prostate and most prostate tumors contain a small number of cells called luminal progenitors that, unlike the bulk of cancer cells, are generally dormant. They behave like stem cells, lacking expression of the molecules targeted by current cancer treatments. As a result, these cells evade prostate cancer treatments such as chemotherapy and radiation, which generally target and eliminate cells that are rapidly multiplying and dividing. Unlike most prostate cancer cells, these dormant, stem-like cells are also less dependent on androgens, making them relatively unresponsive to chemical castration or hormone therapy, approaches designed to “starve” tumors by depriving them of their androgen fuel.
“The existence of a population of quiescent or slow-cycling cells in the prostate has been suggested, but their identity and characteristics were unknown because they are rare and very difficult to study,” explains Dingxiao Zhang, PhD, an Assistant Professor with the Department of Pharmacology and Therapeutics at Roswell Park and first author on the new study. “We were able to identify a unique population of cells that might serve as the origin of treatment-resistant prostate cancer. Our genetic model paves the way toward the next step, which is the development of therapies that can target these dormant cancer cells, which are expected to significantly improve the treatment of prostate cancer and delay or even prevent its recurrence.”
This research was supported by grants from the National Cancer Institute (project nos. R01CA155693 and P30CA016056) as well as the U.S. Department of Defense, Cancer Prevention Research Institute of Texas and Chinese Ministry of Science and Technology, The study, “Histone 2B-GFP Label-Retaining Prostate Luminal Cells Possess Progenitor Cell Properties and Are Intrinsically Resistant to Castration,” is available at cell.com.
This release is also available on the Roswell Park website: https://www.roswellpark.org/media/news/roswell-park-research-identifies-cells-may-be-responsible-prostate-cancer-recurrence
The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email email@example.com. Follow Roswell Park on Facebook and Twitter.